{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:23:39Z","timestamp":1791476619757,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00059-022-05157-z","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T09:03:14Z","timestamp":1674637394000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Europ\u00e4ische Leitlinien Herzinsuffizienz: medikament\u00f6se Therapie","European guidelines on heart failure: pharmacotherapy"],"prefix":"10.1007","volume":"48","author":[{"given":"Sebastian","family":"Grundmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"von zur M\u00fchlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"5157_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"Authors\/Task Force M, McDonagh\u00a0TA, Metra\u00a0M et\u00a0al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24:4\u2013131","journal-title":"Eur J Heart Fail"},{"key":"5157_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","volume":"23","author":"GMC Rosano","year":"2021","unstructured":"Rosano\u00a0GMC, Moura\u00a0B, Metra\u00a0M et\u00a0al (2021) Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 23:872\u2013881","journal-title":"Eur J Heart Fail"},{"key":"5157_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","volume":"6","author":"SJ Greene","year":"2021","unstructured":"Greene\u00a0SJ, Butler\u00a0J, Fonarow\u00a0GC (2021) Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed. JAMA Cardiol 6:743\u2013744","journal-title":"JAMA Cardiol"},{"key":"5157_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray\u00a0JJ, Packer\u00a0M, Desai\u00a0AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"5157_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez\u00a0EJ, Morrow\u00a0DA, DeVore\u00a0AD et al (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N\u00a0Engl J Med 380:539\u2013548","journal-title":"N Engl J Med"},{"key":"5157_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter\u00a0R, Senni\u00a0M, Belohlavek\u00a0J et\u00a0al (2019) Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 21:998\u20131007","journal-title":"Eur J Heart Fail"},{"key":"5157_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW, Pieske\u00a0B, Anstrom\u00a0KJ et\u00a0al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 382:1883\u20131893","journal-title":"N Engl J Med"},{"key":"5157_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"5157_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and renal outcomes with eEmpagliflozin in heart failure. N\u00a0Engl J Med 383:1413\u20131424","journal-title":"N Engl J Med"},{"key":"5157_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad\u00a0F, Ferreira\u00a0JP, Pocock\u00a0SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a\u00a0meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396:819\u2013829","journal-title":"Lancet"},{"key":"5157_CR11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund\u00a0LH, Claggett\u00a0B, Liu\u00a0J et al (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230\u20131239","journal-title":"Eur J Heart Fail"},{"key":"5157_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland\u00a0JGF, Bunting\u00a0KV, Flather\u00a0MD et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart\u00a0J 39:26\u201335","journal-title":"Eur Heart J"},{"key":"5157_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in heart failure with a\u00a0preserved ejection fraction. N\u00a0Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"5157_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Claggett\u00a0B et\u00a0al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med 387:1089\u20131098","journal-title":"N Engl J Med"},{"key":"5157_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, Schwartz\u00a0JH, Gundapaneni\u00a0B et\u00a0al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05157-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T16:03:02Z","timestamp":1678896182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05157-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5157"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05157-z","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"19 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Grundmann und C.\u00a0von zur M\u00fchlen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}